IVERIC bio’s Avacincaptad Pegol Receives Breakthrough Therapy Status from FDA for Geographic Atrophy Treatment
IVERIC bio, Inc. announces U.S. FDA Breakthrough Therapy designation for avacincaptad pegol (Zimura®), a novel investigational complement C5 inhibitor for treating Geographic atrophy (GA) secondary to ...
FDA Approves Neuren Pharmaceutical’s Phase II Trial of NNZ-2591 for Prader-Willi Syndrome
The FDA has approved Neuren Pharmaceuticals' Phase 2 clinical trial for its NNZ-2591 drug for children with Prader-Willi syndrome, a neurological disorder with no approved treatment options. The trial ...